Next Article in Journal
CK2 Pro-Survival Role in Prostate Cancer Is Mediated via Maintenance and Promotion of Androgen Receptor and NFκB p65 Expression
Next Article in Special Issue
Special Issue “Targets, Tracers and Translation Novel Radiopharmaceuticals Boost Nuclear Medicine”
Previous Article in Journal
Cysteine Cathepsin Protease Inhibition: An update on its Diagnostic, Prognostic and Therapeutic Potential in Cancer
Previous Article in Special Issue
Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13

Department of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(2), 88; https://0-doi-org.brum.beds.ac.uk/10.3390/ph12020088
Submission received: 11 June 2019 / Accepted: 12 June 2019 / Published: 13 June 2019
In our paper [1], an error unfortunately occurred in Figure 1. We therefore would like to provide the readers with the corrected figure and apologize for this inconvenience.

Reference

  1. Klingler, M.; Rangger, C.; Summer, D.; Kaeopookum, P.; Decristoforo, C.; von Guggenberg, E. Cholecystokinin-2 Receptor targeting with novel C-terminally stabilized HYNIC-Minigastrin Analogs radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Amino acid sequence and chemical structure of (a) HYNIC-MGS5 and (b) HYNIC-MGS11.
Figure 1. Amino acid sequence and chemical structure of (a) HYNIC-MGS5 and (b) HYNIC-MGS11.
Pharmaceuticals 12 00088 g001

Share and Cite

MDPI and ACS Style

Klingler, M.; Rangger, C.; Summer, D.; Kaeopookum, P.; Decristoforo, C.; von Guggenberg, E. Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13. Pharmaceuticals 2019, 12, 88. https://0-doi-org.brum.beds.ac.uk/10.3390/ph12020088

AMA Style

Klingler M, Rangger C, Summer D, Kaeopookum P, Decristoforo C, von Guggenberg E. Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13. Pharmaceuticals. 2019; 12(2):88. https://0-doi-org.brum.beds.ac.uk/10.3390/ph12020088

Chicago/Turabian Style

Klingler, Maximilian, Christine Rangger, Dominik Summer, Piriya Kaeopookum, Clemens Decristoforo, and Elisabeth von Guggenberg. 2019. "Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13" Pharmaceuticals 12, no. 2: 88. https://0-doi-org.brum.beds.ac.uk/10.3390/ph12020088

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop